Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 12/20 | 0.67 |
| ▸ | NTSR1 | P30989 | 12/20 | 0.67 |
| ▸ | SORT1 | Q99523 | 12/20 | 0.67 |
| ▸ | NPY4R | P50391 | 4/20 | 0.61 |
| ▸ | NPY1R | P25929 | 3/20 | 0.61 |
| ▸ | NPY2R | P49146 | 2/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30436277 | 0.93 | NTSR1 (0.60) | NTSR2NTSR1SORT1NPY4RNPY1R | |
| SCHEMBL31738532 | 0.93 | NTSR1 (0.76) | NTSR2NTSR1SORT1 | |
| SCHEMBL2549334 | 0.90 | NTSR2 (0.57) | NTSR2NTSR1SORT1OPRM1OPRK1 | |
| SCHEMBL2549331 | 0.90 | NTSR2 (0.57) | NTSR2NTSR1SORT1OPRM1OPRK1 | |
| SCHEMBL29419429 | 0.90 | OPRM1 (0.59) | NTSR2NTSR1SORT1OPRM1OPRK1 | |
| SCHEMBL31634123 | 0.90 | NTSR2 (0.60) | NTSR2NTSR1SORT1NPY4ROPRM1 | |
| SCHEMBL30053247 | 0.90 | KDM1A (0.62) | NTSR2NTSR1SORT1NPY4RNPY1R | |
| SCHEMBL32664435 | 0.90 | NTSR2 (0.58) | NTSR2NTSR1SORT1OPRM1 | |
| SCHEMBL29477118 | 0.90 | KDM1A (0.60) | NTSR2NTSR1SORT1NPY4RNPY1R | |
| SCHEMBL30686901 | 0.90 | NTSR1 (0.72) | NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-07-31 | — | — | US | disclosed |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20240269269-A1 | Self-Assembling Nanoparticles | VACCITECH NORTH AMERICA, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| CN-118103059-A | Self-assembled nanoparticles based on amphiphilic peptides | 巴林萨斯生物疗法北美公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4294431-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | Vaccitech North America, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022177993-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | VACCITECH NORTH AMERICA, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | IAPP, BRCA1, ANXA11 | NTSR2 2402/4885NTSR1 2184/4885SORT1 1791/4885 |
| US-20240269269-A1 | Self-Assembling Nanoparticles | UBE2B, CD4, UBE2G2 | NTSR2 2271/4885NTSR1 1766/4885SORT1 4858/4885 |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | IL2, IFNG, ICOS | NTSR2 1093/4885NTSR1 1434/4885SORT1 1498/4885 |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | UBE2B, CD4, HRH1 | NTSR2 2280/4885NTSR1 1763/4885SORT1 4858/4885 |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | VIP, HM13, SPPL2B | NTSR2 2537/4885NTSR1 2194/4885SORT1 1049/4885 |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | MYD88, ICOS, CD4 | NTSR2 2395/4885NTSR1 1840/4885SORT1 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.